Arming the Immune System to Kill Cancer

Our “off the shelf” stem cells deliver a viral payload that first kills cancer cells locally, and then supercharges the immune system to fight metastatic disease.

A blue gloved hand holding a prescription bottle.

We are developing a new generation of targeted immunotherapies that  attack solid tumors, and then teach the immune system to hunt down cancer cells elsewhere in the body.

A person in blue gloves is filling a container with liquid.

Where does the “Calidi” name come from?

The Calidi name is derived from the spanish “caliente” meaning heat, which signifies that Calidi’s cancer treatment transforms immunologically “cold” tumors, which the immune system is unaware of,  becoming “hot” following Calidi’s treatment. The immune system is thus engaged, and attacks the primary tumor and also distant metastases.

Discover the latest from our facility

In the Pipeline: Next-Generation Therapies

Explore Calidi Biotherapeutics' robust and evolving lineup of innovative immunotherapies, each designed with precision and a vision for a healthier future.

A person in a lab coat working on a machine.

Meet the Visionaries Behind Calidi

Get to know the dedicated team at Calidi Biotherapeutics. A blend of experts and innovators, each member plays a pivotal role in our mission to redefine cancer treatment.

A man and woman in lab coats looking at something.

Calidi Newsroom:
Stay Updated

Dive into the latest updates, research findings, and announcements from Calidi Biotherapeutics. Stay informed about our strides in the world of immunotherapy.

A close up of a cell in the air.

Latest News

Press Release

Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that it entered into a collaboration agreement with SIGA Technologies (Nasdaq: SIGA) in the first quarter of 2024, to support the development of Calidi’s systemic and targeted RTNova (CLD-400) virotherapy platform, which has the potential to provide a universal treatment for all tumor types.

June 10, 2024
Discover More
Discover More
Press Release

Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the presentation of three abstracts in a poster session during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

June 3, 2024
Discover More
Discover More
Press Release

Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Calidi Biotherapeutics, Inc. (NYSE American: CLDI), a clinical-stage biotechnology company, has entered a definitive agreement for the immediate exercise of Series B and C warrants, expected to generate approximately $2.1 million. The new unregistered warrants issued will have a five-and-a-half-year term and an exercise price of $0.30 per share, pending shareholder approval. The proceeds will support Calidi's clinical and pre-clinical programs, operational expenses, and working capital.

May 31, 2024
Discover More
Discover More

A talented, seasoned group of world-class executives, doctors, and scientists producing revolutionary work.

Learn more